Nivolumab
Childhood Solid Tumor
Australian & New Zealand Children's Haematology/Oncology Groupmonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the Childhood Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
OTL-38 Mayo Clinic | Phase 3 | B |
Carboplatin Samsung Medical Center | Phase 2 | B |
gw786034 Samsung Medical Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →